Emerging evidence · Grade B
GHK-Cu
GHK-Cu (Copper Peptide GHK-Cu)
Score
72 / 100
Discovered
1973
Class
Copper tripeptide
Status
Cosmetic ingredient
TL;DR
01
A naturally occurring copper-binding tripeptide (Gly-His-Lys) first isolated from human plasma in 1973; its levels in the body decline with age.
02
It is the best-evidenced peptide in the 'healing' group for one specific use — topical skin: small controlled studies on aged skin report improved firmness, elasticity, and reduced fine lines.
03
Its wound-healing, collagen-stimulating, and anti-inflammatory effects are well documented in cell and animal models.
04
Injectable or systemic use, by contrast, has no human trials — the human evidence is topical and cosmetic.
05
Much of the foundational literature comes from the peptide's discoverer and his company, which is worth keeping in mind when weighing the broader health claims.
Human topical studies
Yes (small)
aged-skin cosmetic RCTs
Systemic human trials
None
injectable use unstudied
Preclinical base
Broad
wound, collagen, angiogenesis
Regulatory
Cosmetic ingredient
not an approved drug
Main use
Topical skin/hair
creams, serums
Part 01 · How it works
Mechanism.
GHK-Cu is a small peptide that carries a copper ion and naturally circulates in the body, declining as we age. It appears to switch on tissue-repair programs — stimulating collagen and elastin production, attracting repair cells, calming inflammation, and supporting new blood-vessel growth. Applied to skin, small human studies show it can improve the look of aged skin. Its broader 'regenerative' reputation, though, mostly rests on cell and animal work, and injecting it for whole-body benefits has not been tested in people.
A copper-carrying repair signal the body already makes and loses with age. Rubbed on skin, it measurably helps in small studies; injected for bigger claims, it's untested.
Copper delivery
Binds Cu²⁺ with an affinity similar to albumin's copper-transport site, delivering copper to remodeling enzymes.
Matrix synthesis
Stimulates collagen, elastin, glycosaminoglycan, and metalloproteinase/anti-protease production in fibroblasts.
Repair signaling
Chemoattracts repair cells, supports angiogenesis, and modulates inflammation and antioxidant defenses.
Evidence stage
Small human topical studies for skin; broad cell/animal data; no systemic human trials.
Part 02 · Dosing & administration
How it's taken.
Community-reported · unregulatedValues below reflect commonly reported community protocols for GHK-Cu. These are anecdotal and unregulated — not clinically validated and not a recommendation. Provided for educational purposes only — this is not medical advice and not instructions for self-administration. Consult your healthcare provider before making any health decision.
Wk 1–2
1 mg/day
Subcutaneous, once daily (often before bed) — loading half of a 30-day cycle
TARGET
Wk 3–4
2 mg/day
Escalated dose; finish the 30-day cycle, then rest before repeating
·
Injectable GHK-Cu dosing is community/practice-pattern based (commonly ~1–2 mg/day SC, ~5 days/week, in 30-day cycles) — not trial-validated.
·
The strongest evidence is topical (~1–3% in serums/creams); systemic injection is off-label and unregulated.
·
Copper is cumulative — stacking multiple copper-peptide products or long uninterrupted courses raises copper-overload concerns, which is why protocols cycle with rest periods.
Need help with reconstitution?
Use the free peptide calculator for dilution, unit conversion, and injection volume.
Part 03 · Safety
Side effects, rare serious events, who shouldn't.
Common
Topical irritation
Occasional redness or sensitivity; generally well tolerated on skin.
Uncommon
Contact sensitivity
Possible with copper sensitivity.
Rare
Serious · rare
Systemic copper exposure (injectable)
Injected/systemic use is unstudied; copper handling is a theoretical concern.
Uncharacterized
Long-term systemic safety
No systemic human safety data.
Unknown
Product-quality risk (injectable)
Injectable GHK-Cu is compounded/research-grade and unregulated.
Source-dependent
Absolute · do not use
×
Known hypersensitivity to GHK-Cu, copper peptides, or any component
×
Wilson's disease or copper metabolism disorders
×
Pregnancy or breastfeeding
×
Children under 18
×
Active skin cancer at application site (may promote tissue remodeling)
Relative · discuss first
!
Copper metabolism disorders (e.g., Wilson's disease) — avoid systemic exposure
!
Pregnancy or breastfeeding — systemic use not studied
!
Known copper or peptide sensitivity
!
Anyone seeking injectable systemic benefits — only topical use is evidence-backed
Interactions
Copper chelators (penicillamine, trientine)
May reduce efficacy of copper peptide by chelating copper component
Moderate
Topical retinoids
Combined use may increase skin irritation; stagger application times
Minor
Topical acids (AHA, BHA, vitamin C at low pH)
Acidic pH may degrade peptide; separate application times by 30 minutes
Minor
Labs to monitor
Serum Copper
Baseline and every 3 months
Monitor copper levels with copper peptide use
Ceruloplasmin
Baseline and every 3 months
Copper metabolism assessment
Zinc Level
Baseline and every 3 months
Copper supplementation can deplete zinc
CMP (Comprehensive Metabolic Panel)
Baseline and every 3 months
Liver function (copper is hepatically metabolized)
Part 04 · Evidence
How strong is the evidence?
72
Grade B
Grade B, Emerging — and, unlike its 'healing peptide' peers, partly on real human data. Small controlled topical studies support cosmetic skin benefits, and the preclinical base is broad. The limits: those human studies are small and often industry-linked, and systemic/injectable use is entirely unstudied.
Mechanistic plausibility
Well-characterized copper delivery and matrix-synthesis effects; an endogenous molecule.
80
Human evidence
Small controlled topical/cosmetic studies on aged skin; no systemic human trials.
60
Safety & tolerability
Long topical cosmetic use with a benign profile; systemic safety uncharacterized.
82
Durability
Topical benefits documented over study periods; long-term and systemic durability unknown.
62
Independence
Much foundational literature is from the discoverer's company — a real conflict-of-interest caveat.
55
Part 05 · Research log
Every study we cite.
We list each study with its methodology, funding source, and our quality grade. Flagged studies aren't dismissed — they're tagged so you can weigh them.
01
2008
J Biomater Sci Polym Ed Flagged
The human tripeptide GHK and tissue remodeling (review)
Summarizes GHK-Cu's remodeling biology and notes controlled studies on aged skin showing improved firmness, elasticity, and reduced fine lines/photodamage.
Narrative review (discoverer-authored) · Authored by the discoverer (commercial interest); useful synthesis but not independent.
PMID 18644225 ↗
Moderate (review, conflicted)
02
2017
Wound Repair Regen Flagged
GHK-Cu liposomes accelerate scald wound healing in mice
GHK-Cu liposomes promoted endothelial proliferation and angiogenesis and shortened wound-healing time in mice vs free GHK-Cu.
Mouse scald model + human endothelial cells · Independent group, but animal/cell model.
PMID 28370978 ↗
Moderate (preclinical)
03
2018
Int J Mol Sci Flagged
Regenerative and protective actions of GHK-Cu (gene-data review)
Maps broad biological actions to multiple gene pathways; catalogs protective and regenerative claims across tissues.
Narrative/gene-expression review (discoverer-authored) · Discoverer-authored; broad claims not all independently trialed.
PMID 29986520 ↗
Low-Moderate (review, conflicted)
Evidence against
What didn't work, and where the evidence is thin.
Every publication is incentivized to tell you a peptide works. We catalogue the null results, failed trials, and mechanism limits we found in the same literature — so you can weigh them against the upside, with your provider.
01
The human evidence is topical and cosmetic — systemic use is unstudied
Mechanism limit J Biomater Sci Polym Ed · 2008
The controlled human data supports GHK-Cu applied to skin for cosmetic improvement. There are no human trials of injected or systemic GHK-Cu for the broader 'whole-body regeneration' claims it is often sold on.
What this means: GHK-Cu is a legitimate cosmetic skin ingredient. Using it as an injectable systemic healing agent goes well beyond where the human evidence reaches.
PMID 18644225 ↗
02
Much of the literature comes from the discoverer's company
Mechanism limit Int J Mol Sci · 2018
Several of the most-cited GHK-Cu reviews and claims originate with the peptide's discoverer and his commercial venture, and the broadest health claims are not all independently replicated.
What this means: The core skin data is credible, but the expansive 'protects everything' narrative should be read with the commercial source in mind.
PMID 29986520 ↗
Part 06 · Cost & access
Where it's available, at what price.
United States
Cosmetic ingredient
Widely available in topical skincare (OTC cosmetic). Injectable/systemic GHK-Cu is not an approved drug and is compounded/research-grade.
Cosmetic products vary; injectable is grey-market
European Union
Cosmetic ingredient
Permitted in cosmetics; not an approved medicine for systemic use.
Cosmetic pricing
United Kingdom
Cosmetic ingredient
Permitted in cosmetics; systemic use not approved.
Cosmetic pricing
Canada
Cosmetic ingredient
Permitted in cosmetics; systemic use not approved.
Cosmetic pricing
The Peptide Column takes no affiliate commission from any source. GHK-Cu is a legitimate topical cosmetic ingredient; injectable/systemic GHK-Cu is not an approved medicine and is unregulated. We link only to clinician-directed care, never to sellers.
Part 07 · Your appointment
Questions to bring.
01
For my degree of skin aging or hair thinning, is topical GHK-Cu sufficient or would injectable/systemic GHK-Cu provide additional benefit?
02
Are there any concerns about systemic copper accumulation with long-term use, particularly if I take copper-containing supplements?
03
How does GHK-Cu compare to retinoids, peptide growth factors, or platelet-rich plasma for my specific skin concern?
04
Is there any risk of GHK-Cu stimulating tumor growth given its pro-angiogenic and proliferative effects?
References
Every citation, numbered.
Citation list. For our editorial read of each study — including bias flags and quality grades — see the Research log above.
- 01. The human tripeptide GHK and tissue remodeling (review) · J Biomater Sci Polym Ed, 2008 · PMID 18644225 ↗
- 02. GHK-Cu liposomes accelerate scald wound healing in mice · Wound Repair Regen, 2017 · PMID 28370978 ↗
- 03. Regenerative and protective actions of GHK-Cu (gene-data review) · Int J Mol Sci, 2018 · PMID 29986520 ↗
- 04. Cosmetic-ingredient literature. GHK-Cu topical skin-aging studies